SCHEMBL2348518

SCHEMBL2348518

Cc1ccnn(CC(=O)O)c1=N

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.47
LMNA P02545 1/20 0.42
GABRP O00591 2/20 0.42
GABRD O14764 2/20 0.42
GABRA1 P14867 2/20 0.42
GABRB1 P18505 2/20 0.42
GABRG2 P18507 2/20 0.42
GABRB3 P28472 2/20 0.42
GABRA5 P31644 2/20 0.42
GABRA3 P34903 2/20 0.42
GABRA2 P47869 2/20 0.42
GABRB2 P47870 2/20 0.42
GABRA4 P48169 2/20 0.42
GABRE P78334 2/20 0.42
GABRA6 Q16445 2/20 0.42
GABRG1 Q8N1C3 2/20 0.42
GABRG3 Q99928 2/20 0.42
GABRQ Q9UN88 2/20 0.42
ALDH1A1 P00352 3/20 0.40
TDP1 Q9NUW8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2175235 0.78 MAPK1 (0.68) MAPK1LMNAALDH1A1TDP1L3MBTL1
SCHEMBL3091100 0.72 LMNA (0.64) LMNAGABRPGABRDGABRA1GABRB1
SCHEMBL14656717 0.71 MAPK1 (0.42) MAPK1LMNAALDH1A1TDP1L3MBTL1
SCHEMBL16968020 0.71 MAPK1 (0.46) MAPK1LMNAALDH1A1TDP1L3MBTL1
SCHEMBL2345107 0.71 TSHR (0.39) MAPK1LMNAGABRPGABRDGABRA1
SCHEMBL15330740 0.71 KDM4E (0.47) MAPK1LMNAALDH1A1TDP1L3MBTL1
SCHEMBL25342529 0.69 NLRP3 (0.47) MAPK1LMNAALDH1A1KDM4EPOLB
SCHEMBL1270152 0.68 MAPK1 (0.42) MAPK1LMNAALDH1A1TDP1L3MBTL1
SCHEMBL2351094 0.68 LMNA (0.45) LMNAGABRPGABRDGABRA1GABRB1
SCHEMBL2352509 0.68 LMNA (0.45) LMNAGABRPGABRDGABRA1GABRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1932835-B1 METHOD FOR PRODUCING 2,3-DIHYDROPYRIDAZINE COMPOUND SUMITOMO CHEMICAL CO (JP) 2013-12-25 EP disclosed
EP-1930331-B1 METHOD FOR PRODUCING IMIDAZO[1,2-b]PYRIDAZINE COMPOUND SUMITOMO CHEMICAL CO (JP) 2013-03-13 EP disclosed
US-8334379-B2 Process for producing imidazo[1,2-b]pyridazine compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-12-18 US disclosed
US-8008485-B2 Process for producing 2,3-dihydropyridazine compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-30 US disclosed
US-20100234597-A1 PROCESS FOR PRODUCING IMIDAZO[1,2-b]PYRIDAZINE COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-09-16 US disclosed
US-20090105475-A1 PROCESS FOR PRODUCING 2,3-DIHYDROPYRIDAZINE COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-04-23 US disclosed
EP-1932835-A1 METHOD FOR PRODUCING 2,3-DIHYDROPYRIDAZINE COMPOUND Sumitomo Chemical Company, Limited (JP) 2008-06-18 EP disclosed
EP-1930331-A1 METHOD FOR PRODUCING IMIDAZO[1,2-b]PYRIDAZINE COMPOUND Sumitomo Chemical Company, Limited (JP) 2008-06-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105475-A1 PROCESS FOR PRODUCING 2,3-DIHYDROPYRIDAZINE COMPOUND DDC, DHPS, QDPR MAPK1 230/4885LMNA 3177/4885GABRP 1446/4885
US-20100234597-A1 PROCESS FOR PRODUCING IMIDAZO[1,2-b]PYRIDAZINE COMPOUND CYP1B1, CYP4Z1, CYP2J2 MAPK1 581/4885LMNA 3651/4885GABRP 710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.